| row-start col-md-7 #top-section top-section #about-section no-pad-bottom-section |
Foreword
The Midlands is home to one of the most important Life Sciences ecosystems in the UK. The region has the second largest concentration of MedTech companies in the UK, and it is a major centre for clinical research with which stems from its high number of world class universities, research centres and incubators.
The Midlands has a rich set of research and innovation assets and is home to 27 Universities supported by a network of 54 Further Education Colleges. Midlands Health Innovation is a collaboration of eight Universities combining their collective excellence to unite the power of University research with the unique strengths of Midlands industry to drive cutting edge innovation and skills development.
The Midlands is an established and well-connected eco-system, offering an unparalleled blend of businesses, Universities and research translation centres, coupled with strong collaboration, research and clustering activities. Nottingham is home to BioCity which is one of the largest incubators in Europe housing more than 200 companies specialising in Contract Research Services, Therapeutics, Environmental and Wellness.
We have gathered together delegates from across the Midlands region who are keen to collaborate and work with international companies and organisations. Further details can be found below:
| row-end col-sm-12 col-md-5 |
|
|||
|
|||
| Louise Stock is the Life Sciences and Bioscience Sector Specialist at the Department for International Trade East Midlands and Midlands Engine Life Sciences Advisor. She is also is the Middle East and North Africa specialist. | |||
| Contact Louise: | |||
| Tel: +44 (0)7769 301805 | |||
| Email: louise.stock@trade.gov.uk | |||
| About the Department for International Trade: | |||
| The Department for International Trade (DIT) helps businesses export, drives inward and outward investment, negotiates market access and trade deals, and champions free trade. | |||
| Visit: great.gov.uk | |||
| row-start col-md-10 #top-section top-section #about-section colour-section no-pad-bottom-section |
UK Midlands Delegate Profiles:
BIO International Convention 2022
13–16 June 2022
We have gathered together delegates from across the Midlands region who are keen to collaborate and work with international companies and organisations:
| row-start col-xs-12 colour-section row-end |
Adamson Jones, part of Gateley
Category:
Other,Intellectual Property
Company Profile:
Adamson Jones, part of Gateley, provides intellectual property advice and protection in the UK, Europe and throughout the world. Our medical device patent attorneys have backgrounds in a wide range of technical disciplines, from physics and mechanical engineering to pharmaceuticals and biotechnology, providing a cross-disciplinary service that ensures the best outcomes for our clients. We work with start-ups and spin-outs who are often at the beginning of their IP journey, as well as managing large IP portfolios for multi-national companies with in-house IP functions.
Current operating markets:
Global with particular focus in UK, Europe, North America, and Asia.
Would like to connect with companies in the following categories:
Biotech - Food & Agriculture , Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D , Digital Health , Medical Device or Technology , Synthesis, Analytic, Diagnostic Services.
Back to Top
Category:
Biotech - Food & Agriculture , Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D , Medical Device or Technology , Other Providing IP Services
Company Profile:
We are an IP firm based in Stratford -upon-Avon, Cambridge, Oxford and London, specialising in Life Sciences, Pharmaceuticals, Chemistry and Medical Technology sectors. We are a team of highly skilled and commercially driven UK and European Qualified Patent Attorneys. As IP specialists we can take clients through the entire IP journey from concept to drafting, prosecution, EP oppositions, litigation, and commercialisation. Avidity IP have over 30 years of experience in dealing with complex legal issues around IP rights and maximising commercial value. Avidity IP has developed into a highly respected organisation, servicing a diverse range of multi-national clients, as well building strong relations with our foreign business partners.
Current operating markets:
USA (West and East Coast), Far East Asia , India ,UK.
Would like to connect with companies in the following categories:
Academic, Tech Transfer , Biotech - Food & Agriculture , Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D , Digital Health , Institute, Hospital Research, Medical Device or Technology , Synthesis, Analytic, Diagnostic Services.
Back to Top
Category:
Academic, Tech Transfer , Biotech - Food & Agriculture , Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D , CMO, CRO , Digital Health , Institute, Hospital Research, Medical Device or Technology , Synthesis, Analytic, Diagnostic Services
Company Profile:
Bio-Diagnostics Ltd (1979). Research driven IVD manufacturer, (Component assembly to finished kits), controls and reagents. Supplying global markets FDA approved / CE marked products, including the 3 minute COVID-19 BioCard™. Bio-Diagnostics technology is recommended by the CDC in the USA for HSV2 (Genital Herpes) infection, affecting 491M people. (Global distributor opportunities available). Offering branded/private label contract manufacture, our proprietary technologies are available under licence to third parties, commonly via collaborative contract development. Through such synergies, toxins, infectious diseases and epidemiological tests have successfully been developed. Yield-diminishing crop viruses can be quickly identified in-the-field. Limitless applications in veterinary and human markets. Actively seeking partners who require access to this proven 3-minute ultrarapid platform for their own applications. Bio-Diagnostics enhanced ultra-rapid technology for the pandemic resulted in the BioCard™. Bringing semi-quantified results, combining a speed faster than LFT with results on a par or better* than laboratory processors without equipment. This unique monitoring tool can make imperfect vaccines perfect by tracking anyone’s waning immunity anywhere. BioCard™ can optimise vaccine rollout by identifying individual vaccine response, evidencing precisely when a booster is necessary to prevent vaccine breakthrough. A key tool in preparation for current and future pandemic waves. www.cdc.gov/std/treatment-guidelines/herpes.
Current operating markets:
Global. North America including USA, Europe, Asia. Australia.
Would like to connect with companies in the following categories:
Academic, Tech Transfer , Biotech - Food & Agriculture , Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D , CMO, CRO , Digital Health , Institute, Hospital Research, Medical Device or Technology , Synthesis, Analytic, Diagnostic Services.
Back to Top
Category:
Digital Health, Medical Device or Technology
Company Profile:
Advanced Wearable AI technology to treat neurological conditions.
Current operating markets:
Europe and United States.
Would like to connect with companies in the following categories:
Biotech or Pharma, Therapeutic R&D , CMO, CRO, Digital Health, Institute, Hospital Research, Medical Device or Technology.
Back to Top
Category:
Academic, Tech Transfer , Biotech - Food & Agriculture , Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D , Medical Device or Technology
Company Profile:
Buttonwood Marketing Limited is an award-winning marketing agency specialising in scientific communications. Based in the UK, but with clients all over the world, Buttonwood Marketing creates technical content that raises client profiles, promotes brand values, improves SEO and highlights clients’ key differentiators. The content created by our staff is leveraged in published media, in digital marketing, on client websites and in social media. Typically, this content would include thought-leading articles, editorial, case studies and press releases, and their value is recognised by the editors of leading technical and trade media.
Current operating markets:
Global.
Would like to connect with companies in the following categories:
Biotech or Pharma, Therapeutic R&D , CMO, CRO, Digital Health, Institute, Hospital Research, Medical Device or Technology.
Back to Top
Category:
Biotech or Pharma, Therapeutic R&D
Company Profile:
Celentyx Ltd are a CRO specialising in bespoke assay services focused on human immunology, immuno-oncology, fibrosis and neuroinflammation. Celentyx has established local access to fresh, disease relevant patient tissue and blood, allowing us to set up customized assays with human primary cells (healthy and/or diseased). A recent addition to the suite of assays is the ability to culture and perform functional investigation of microglia (from human brain or microglia differentiated from human monocytes). We benefit from the world-leading expertise of the neighbouring MRC Centre for Immune Regulation and Institute of Translational Medicine (Birmingham, UK). Our assays support our clients in candidate selection, screening, differentiation, mechanism of action, target discovery and proof of concept studies. Our technologies include multi-colour flow cytometry, multiplex cytokine analysis, high-throughput confocal microscopy, qPCR, RNAseq, and electrophysiology.
Current operating markets:
GUK, US, EU, Japan.
Would like to connect with companies in the following categories:
Biotech or Pharma, Therapeutic R&D; Biotech - Food & Agriculture; Biotech - Industrial & Environmental.
Back to Top
Category:
CMO, CRO
Company Profile:
Cellomatics Biosciences is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology, Immuno-oncology, Immunology, Inflammation and Respiratory therapeutic areas. Based in Nottingham UK our experienced scientific team offer bespoke and innovative preclinical in vitro bioassay services to support our client’s drug development programmes. We work with diverse group of global clients including early start-ups, virtual/small to medium sized Biotechnology and Pharmaceutical companies. Our scientific personnel have expertise in diverse technologies and therapeutic areas. With years of experience, they have the skills needed to understand your requirements and deliver bespoke, innovative and practical solutions. Over the years, we have developed, optimised and validated several clinically relevant in vitro disease models within the relevant therapeutic areas. At Cellomatics, we believe in efficient project management to ensure the delivery of high-quality work and complete client satisfaction.
Current operating markets:
Our clients are based globally. About 50% of the work is generated from UK-based clients with the remaining from global companies including Asia, EU and some parts of US/Canada.
Would like to connect with companies in the following categories:
Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D.
Back to Top
Charnwood Campus Management Ltd
Category:
Other, Science Park
Company Profile:
Charnwood Campus Science, Innovation and Technology Park is a business led life sciences ecosystem that provides world-class flexible laboratories, specialist manufacturing facilities and a comprehensive support package for life science and associated companies. The site offers immediately occupiable laboratory and office space, and 4.97 ha of development land. As a UK Centre of Excellence, Enterprise Zone and the UK’s first Life Science Opportunity Zone, campus offers the following benefits to companies: The Charnwood Life Science Talent and Skills Institute, a partnership with local FEI/HEI providers to align educational centres with industry needs to facilitate recruitment and upskilling of employees. The Charnwood Campus Mentor programme, which comprises Business Support, Peer to Peer Mentoring, a range of industry demand driven events and Knowledge Exchange/Innovation programs with academic partners. Soft landing packages to facilitate relocation to the Campus. An experienced facilities management and development team to expedite relocation, facilitate accommodation modifications/new build requirements. Charnwood Campus is home to the Almac Pharmaceutical drug development services, research, and manufacturing facility, 3M Health Care’s national centre, Kindeva Drug Delivery’s manufacturing and R&D facility, Charnwood Molecular, and others.
Current operating markets:
Global.
Would like to connect with companies in the following categories:
Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D , CMO, CRO , Digital Health , Medical Device or Technology , Synthesis, Analytic, Diagnostic Services.
Back to Top
Category:
Biotech or Pharma, Therapeutic R&D , CMO, CRO , Synthesis, Analytic, Diagnostic Services
Company Profile:
Charnwood Molecular Limited is a leading and award winning UK-based CRO providing integrated drug discovery solutions from target to lead candidate. We are passionate about helping our customers to deliver life changing medicines - we live for the thrill of discovery.
Current operating markets:
US, Europe, Asia.
Would like to connect with companies in the following categories:
Academic, Tech Transfer , Biotech - Food & Agriculture , Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D , Institute, Hospital Research.
Back to Top
Category:
Medical Device or Technology
Company Profile:
DHC Innovations specialise in enabling new SME entrants to UK healthcare markets, with over 40 years experience and knowledge gained in medical devices, logistics, procurement, regulatory, operational and project management. Our aim is to help you help others.
Current operating markets:
We currently operate in the UK and EU in healthcare and life science markets.
Would like to connect with companies in the following categories:
Institute, Hospital Research, Medical Device or Technology , Synthesis, Analytic, Diagnostic Services.
Back to Top
Category:
CMO, CRO
Company Profile:
HistologiX is the UK’s leading independent GLP-compliant laboratory for the provision of IHC, digital pathology and image analysis solutions, to progress drug development programmes in the pharmaceutical and biotechnology sectors.
Current operating markets:
United Kingdom, Europe, United States of America, Asia/Pacific.
Would like to connect with companies in the following categories:
Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D , CMO, CRO , Institute, Hospital Research, Medical Device or Technology.
Back to Top
Category:
Biotech or Pharma, Therapeutic R&D
Company Profile:
Intelligent OMICS (Intellomx) is transforming drug discovery using artificial intelligence and machine learning. Through the development of a unique set of artificial neural network driven machine learning tools Intellomx interrogate human tissue omics data sets and healthy tissue comparators to develop a comprehensive understanding of molecular pathways in disease to determine the key drivers. Those molecules that are causal to disease, not just correlated. This de novo research yields molecular targets that can then be prosecuted as drug targets or biomarkers. Moreover, Intellomx has developed a Digital Twin capability that reproduces key target pathways in healthy tissue and allows us to understand in silico what the consequences might be of perturbating pathways important to disease tissue in healthy organs thereby understanding any toxicity liability. Intellomx has developed a pipeline of assets focussed on the KRAS pathway for the treatment of non-small cell lung cancer and seeks partnerships to employ the platform towards other disease areas.
Current operating markets:
Europe, US, Asia Pacific.
Would like to connect with companies in the following categories:
Biotech or Pharma, Therapeutic R&D.
Back to Top
Category:
Biotech or Pharma, Therapeutic R&D
Company Profile:
Patch is thin, flexible, comfortable and moisture-resistant, whilst also having a high payload; it does not leave a residue on the skin when it is removed, and has very good adhesion enabling patches to be designed for 1-day or up to 7-day wear. Medherant is developing products for hormone replacement therapy and CNS disorders. The company is also working with a major multinational consumer health company to develop the first patch in a major therapy area. Medherant is seeking additional partners that want to create transdermal delivery forms for their drugs and offers rapid feasibility studies using its proprietary high-throughput system to test multiple prototype formulations on human skin.
Current operating markets:
Europe, US and Canada.
Would like to connect with companies in the following categories:
BBiotech or Pharma, Therapeutic R&D.
Back to Top
Category:
Biotech or Pharma, Therapeutic R&D , Institute, Hospital Research
Company Profile:
The Midlands Health Alliance ( MHA) is and alliance of internationally recognised experts working on cross cutting clinical questions via a joint strategy between the Midlands Biomedical Research Centres, Clinical research Facilities and wider NIHR infrastructure , enabling industry to access leading experts within the NHS.
Current operating markets:
Global.
Would like to connect with companies in the following categories:
Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D , Institute, Hospital Research.
Back to Top
Category:
Other, Academic, Tech Transfer, Regional innovation programme development
Company Profile:
Midlands Innovation Health (MI Health) coordinates and combines the collective excellence of 7 Midlands Innovation universities to deliver improved health and regional growth. Driving disruptive translational interventions and influencing nationally, MI Health draws together a critical mass of innovative regional stakeholders to impact national and global health challenges using local training strengths, expertise, networks, best practice and facilities. Our Board comprises the Universities of Aston, Birmingham, Keele, Leicester, Loughborough, Nottingham and Warwick. We are also members of other regional and national organisations such as Midlands Engine Health and the UK Life Science Cluster of Clusters.
Current operating markets:
Open to all looking to collaborate or work within the Midlands region (UK).
Would like to connect with companies in the following categories:
Academic, Tech Transfer , Biotech - Food & Agriculture , Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D , CMO, CRO , Digital Health , Institute, Hospital Research, Medical Device or Technology , Synthesis, Analytic, Diagnostic Services.
Back to Top
Category:
Biotech - Food & Agriculture , Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D
Company Profile:
Myconeos Ltd utilise a broad selection of molecular, biochemical techniques to identify sexual cycles in fungi and naturally sexually cross fungi that are considered asexual eg Penicillium and Aspergillus species. Our platform technology allows us to naturally breed fungal strains for use in mycoprotein production , biofermentation for colours, aromas, chemical and enzyme production, mycoremediation, silage conditions, plant health and animal health.
Current operating markets:
Fungal cultures for mould ripened cheese productiopn. Mycoprotein production. Biofermentation for enzyme, colours, flavour production.
Would like to connect with companies in the following categories:
Biotech - Food & Agriculture , Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D.
Back to Top
Category:
Biotech or Pharma, Therapeutic R&D
Company Profile:
NanoSyrinx is a discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for the intracellular delivery of protein and peptide biologic drugs. Our approach is unlocking a vast array of intracellular targets which are currently “undruggable” using biological payloads. We raised our oversubscribed Seed round of £6.2m in 2021, backed by a consortium of top-tier investors led by M Ventures (Amsterdam) and Octopus Ventures (London) and supported by IQ Capital, We Are Pioneer Group, UKI2S and Jonathan Milner.
Current operating markets:
NanoSyrinx's operations are currently based in the UK, but the market for our technology platform is global.
Would like to connect with companies in the following categories:
Biotech or Pharma, Therapeutic R&D.
Back to Top
Category:
Biotech or Pharma, Therapeutic R&D , CMO, CRO, Bioinformatics, Machine Learning
Company Profile:
Oncimmune, a global leader in immunodiagnostics is focused on autoantibody biomarker profiling in immuno-oncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the company provides insights to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy. Oncimmune is headquartered in the UK with operations in Germany and USA.
Current operating markets:
Global with particular focus in UK, Europe, North America, and Asia.
Would like to connect with companies in the following categories:
Academic, Tech Transfer , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D , CMO, CRO , Digital Health , Institute, Hospital Research.
Back to Top
Category:
Medical Device or Technology
Company Profile:
Renfrew Group International is a medical device design, development and prototyping company, geared towards rapid commercialisation of marketable product. Based in the East Midlands, we focus on successfully taking the science from the lab to the market. Renfrew Group design, engineer and pilot manufacture a wide variety of technologies for a broad range of organisations, globally. We work across sectors including medical technologies and consumer devices. We are particularly strong in helping companies innovate and get to initial production volumes for trials and product launches. In the Med tech field we have or are currently working on innovations with a spinout from Oxford university, a Cambridge based wearable diagnostics company, creating a comfortable, wearable SPO2 monitor for COPD care at home, a Nottingham university Hospital team on GI imaging and with UCL, Royal Free on a world first bio-artificial liver system. And a novel vaccine delivery system with Loughborough spinout, Nemaura. These examples are sometimes delivered via public innovation funds jointly applied for, but most of our clients are private sector businesses, currently including 2 robotics projects in the medical field. We work every day with our clients in USA, Europe and And Asia.
Current operating markets:
UK, USA, EU, Middle East. Asia.
Would like to connect with companies in the following categories:
Academic, Tech Transfer , Biotech or Pharma, Therapeutic R&D , Medical Device or Technology.
Back to Top
Category:
Medical Device or Technology
Company Profile:
SureScreen believe that early, accurate diagnosis is better than waiting for problems to arise, and a pro-active approach greatly benefits people's health, identifies issues early in their development, prevents accidents from happening and has a positive effect on performance, productivity and reputation. Our mission is to provide the best quality diagnostic products that meet and exceed their customer's expectations at a fair price. We do this through innovating and manufacturing point of care IVD products that can test at the patients side and provide results within 10 minutes.
Current operating markets:
UK, EU, South America, Middle East, SE Asia, Australasia.
Would like to connect with companies in the following categories:
Biotech or Pharma, Therapeutic R&D , Medical Device or Technology.
Back to Top
Category:
CMO, CRO
Company Profile:
Sygnature Discovery is a leading independent integrated drug discovery and non-clinical services company. Private equity-backed since 2017, they operate fully enabled research facilities in Nottingham and Alderley Park, UK, housing over 400 research scientists (over 80% of whom hold a PhD), and has an office presence in Cambridge, MA, and South San Francisco, CA, in the US. Their experienced drug-hunters possess all the professional skills and know-how required to undertake the most demanding of research programs, and drive them from target validation through hit identification, hit-to-lead and lead optimisation to pre-clinical development candidate. Sygnature’s in vivo pharmacology arm was formed by the incorporation of RenaSci, acquired in 2018, into Sygnature’s fully integrated drug discovery platform. In 2020 Sygnature acquired in vivo oncology firm Alderley Oncology and DMPK provider XenoGesis, then in 2022 acquired Peak Proteins. Since 2011, 40 compounds, discovered by Sygnature for partners, have entered pre-clinical development and 20 of these have progressed to clinical trials (Phases I, II and III). In 2017, Sygnature Discovery received the prestigious Queen’s Award for Enterprise for International Trade, and in the last year has won both the Medilink Outstanding Achievement Award and the Bionow Company of the Year Award.
Current operating markets:
Global, with emphasis on Europe, USA, Japan, Middle East.
Would like to connect with companies in the following categories:
Biotech or Pharma, Animal Health, Biotech or Pharma, Therapeutic R&D.
Back to Top
Category:
Academic, Tech Transfer
Company Profile:
Through innovative work with business across research and education, the University of Birmingham is a driver for positive impact and change. One of the top 100 universities globally and ranked 10th in the Russell Group for research excellence the University is the number one most targeted UK university by Top Employers. Business Engagement at University of Birmingham drives innovation through collaborative partnerships with business. Working with organisations of all sizes, from global corporates to local SMEs we develop innovative, transformative projects, translating research from the lab towards the market. Our connected health ecosystem provides support for every step of the drug, device and diagnostic development pipeline, and offers access to a wide range of clinical research, trials and health data expertise, as well as opportunities to work with leading teams and key opinion leaders across the academic and clinical spectrum. Including the UKs largest hospital, a new Health Innovation Campus and access to a diverse and stable patient population of 6 million people, we offer training, research, clinical and trials excellence in oncology, inflammation, healthy ageing, rare disease, immunology and immunotherapy, genomics, maternal health, dentistry, real world data, data driven healthcare and regulatory science.
Current operating markets:
Global.
Would like to connect with companies in the following categories:
Biotech or Pharma, Therapeutic R&D , CMO, CRO , Digital Health , Institute, Hospital Research, Medical Device or Technology.
Back to Top
Category:
Digital Health, Medical Device or Technology, Synthesis, Analytic, Diagnostic Services
Company Profile:
Virtual Autopsy™ is a new medical technology where non-intrusive human autopsies are performed by using a CT Scanner to obtain a full 3D view of the body. Virtual Autopsy Solutions™ has developed a software-based procedure, where the acquired Dicom data is rendered through proprietary software (VizOpsy™). 360-degree rotation may then be used to view and dissect the virtual body in high definition, allowing medical examiners, coroners and pathologists to examine the state of the blood vessels, organs, bones and tissues and thus, determine the cause of death and the manner in which the patient died.
Current operating markets:
UK, CIS Region, South Asia, Middle East.
Would like to connect with companies in the following categories:
Digital Health , Institute, Hospital Research, Medical Device or Technology.
Back to Top
Category:
Biotech - Food & Agriculture , Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D
Company Profile:
Sustainability is now well and truly at the forefront of global discussion. Innovators, pioneers and designers will be the ones to make the biggest difference when developing solutions to address these challenges. The solution for temperature-controlled packaging is simple. Multi-award winning insulated packaging pioneers, Woolcool®, are already challenging the status quo, and have been for over a decade. They produce a wide range of high-performing, sustainable insulated packaging solutions, from short journey, smaller parcels to longer duration, large shipments. Their range includes systems for 2-8C and CRT. They are raising the bar in passive packaging and continue to innovate. Not only do they meet global demands to ensure clients are confidently Cold Chain Compliant, but they are consistently exceeding them. Their solutions ensure safe transportation of temperature sensitive, precious payloads, whilst using truly sustainable, natural and widely recyclable materials. High-performance passive packaging doesn’t need to cost the Earth.
Current operating markets:
UK, EU, USA and Asia.
Would like to connect with companies in the following categories:
Biotech - Food & Agriculture , Biotech - Industrial & Environmental , Biotech or Pharma, Animal Health , Biotech or Pharma, Therapeutic R&D.
Back to Top
